文献速递艾滋病与性传播感染

初治HIV成人启动BIC/FTC/TAF与DTG+3TC后的代谢并发症:多中心前瞻性队列研究

Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in Antiretroviral-therapy-naive Adults With HIV: A Multicenter Prospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2025-01-01

基于西班牙HIV研究网络队列,将340对倾向评分匹配的初治HIV成人分别启动BIC/FTC/TAF或DTG+3TC,比较96周体重、代谢标志物及代谢相关临床事件。两组体重平均增加1.4 kg(95%CI 1.1, 1.8),组间无显著差异,代谢结局及临床事件相似。作者认为TAF的代谢特征不应作为选择两药或三药方案的决策因素。

要点

  • 96周平均体重增加1.4 kg(95%CI 1.1, 1.8),BIC/FTC/TAF与DTG+3TC组间无显著差异。
  • BMI、血脂、肝脂肪变性指数及代谢相关临床事件发生率两组相似。
  • 作者认为选择两药或三药方案时,TAF代谢特征不应作为决策因素。

核心结论

  • 在初治HIV成人全国队列中,启动BIC/FTC/TAF或DTG+3TC后96周体重和血脂呈相似轻度升高,代谢结局或临床事件无显著差异。
  • 作者认为选择两药或三药ART方案时,TAF的代谢特征不应作为决策因素。

研究设计与样本

  • 基于西班牙HIV研究网络队列(CoRIS)的多中心前瞻性队列研究,纳入初治HIV成人,排除乙型肝炎者,按倾向评分匹配后比较BIC/FTC/TAF组与DTG+3TC组,每组340例,随访96周。

主要发现

  • 匹配后每组340例,中位年龄34岁,95%为男性,62%来自西欧。
  • 96周平均体重增加1.4 kg(95%CI 1.1, 1.8),BIC/FTC/TAF组与DTG+3TC组间无显著差异。
  • BMI、血脂水平、肝脂肪变性指数及临床事件(高血压、糖尿病、血脂异常、肝脂肪变性)发生率两组相似。

关键数值与推荐

  • 96周平均体重增加1.4 kg(95%CI 1.1, 1.8),BIC/FTC/TAF组与DTG+3TC组间无显著差异。
  • BMI、血脂、肝脂肪变性指数及代谢相关临床事件发生率两组相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although antiretroviral therapy (ART) has become less toxic over time, its long-term adverse effects remain a concern. In ART-naive people, tenofovir alafenamide (TAF) is frequently prescribed to reduce the toxicity of tenofovir disoproxil fumarate (TDF). However, the metabolic impact of TAF remains a concern. This study aimed to evaluate the metabolic effects of TAF in ART-naive participants. METHODS: We analyzed data from the Cohort of the Spanish HIV Research Network (CoRIS). We included ART-naive participants who initiated either bictegravir/emtricitabine/TAF (BIC/FTC/TAF) or dolutegravir + lamivudine (DTG+ 3TC), matched by propensity score, after excluding those with hepatitis B. We compared changes in weight, metabolic biomarkers, and the incidence of metabolism-related clinical events over 96 weeks. RESULTS: In total, 340 participants were matched in each group. The median age was 34 years, 95% were male, and 62% were from Western Europe. The mean weight gain was 1.4 kg (95% confidence interval [CI]: 1.1, 1.8) after 96 weeks, with no significant differences between the BIC/FTC/TAF and DTG + 3TC groups. Changes in body mass index, lipid levels, hepatic steatosis index, and incidence of clinical events (hypertension, diabetes mellitus, dyslipidemia, and liver steatosis) were also similar between the groups. CONCLUSIONS: In this nationwide cohort of ART-naive individuals, initiation of BIC/FTC/TAF or DTG + 3TC resulted in similar modest increases in weight and lipid levels after 96 weeks, with no significant differences in metabolic outcomes or clinical events. These findings suggest that the metabolic profile of TAF should not be a deciding factor when choosing between 2- and 3-drug ART regimens.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. García-Ruiz de Morales AG, Suárez Robles M, Pérez-Elías MJ, et al. Metabolic Complications After Initiating BIC/FTC/TAF Versus DTG + 3TC in Antiretroviral-therapy-naive Adults With HIV: A Multicenter Prospective Cohort Study. Clin Infect Dis. 2025. PMID: 40155359. doi:10.1093/cid/ciae645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。